# 116-hr-8987: Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020

116-hr-8987, Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020, is a 116th Congress bill sponsored by Rep. Joyce, John [R-PA-13] (R-PA); status Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (as of 2025-11-18).

- Canonical: https://policyrisk.com/legislation/116-hr-8987
- As of: 2025-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 116-hr-8987
- Congress: 116
- Title: Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020
- Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced: 2020-12-16
- Sponsor: Rep. Joyce, John [R-PA-13] (R-PA)
- Cosponsors: 0
- Policy area: Health
- Touches household money: no
- Last recorded action: 2025-11-18

## Summary

Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020 This bill provides tax credits for manufacturing certain priority medicines and establishes an expedited review procedure for drug manufacturers seeking to transition from foreign manufacturing to domestic manufacturing. The Department of Health and Human Services (HHS) must publish annually a list of priority drugs and active pharmaceutical ingredients that (1) are necessary for use in a public health emergency, (2) are at high risk of becoming in short supply, and (3) have a vulnerable global supply chain. The bill provides a tax credit for 50% of a manufacturer's direct and indirect costs incurred in a taxable year for the production of a drug or active ingredient that was on this list in any of the five preceding years. Furthermore, the Food and Drug Administration (FDA) must expedite the review and approval of a supplemental application that seeks to transfer manufacturing of an already-approved drug or active pharmaceutical ingredient to a domestic establishment. (A supplemental application generally involves a change, such as a manufacturing change, to an existing application for FDA market approval.) The bill imposes various requirements for this expedited review, including a deadline for the FDA to take action on such a supplemental application within six months of submission. HHS shall also establish the Facility Transfer Working Group to assist with evaluating such applications and provide advice and feedback to applicants upon request.

## Related bills

- 116-hr-8966: COVID–19 Vaccine Awareness Support Act of 2020
- 116-hr-8855: HERCULES Act
- 116-hr-8830: You Must Be Alive To Vote Act of 2020
- 116-hr-8702: Holding Providers Harmless From Medicare Cuts During COVID–19 Act of 2020
- 116-hr-12: CTF Act
- 116-hr-8621: Child Tax Credit for Pregnant Moms Act of 2020

## Sources
- [116-hr-8987 on Congress.gov](https://www.congress.gov/bill/116th-congress/house-bill/8987)

## Related
- [116-hr-8966: COVID–19 Vaccine Awareness Support Act of 2020](https://policyrisk.com/legislation/116-hr-8966)
- [116-hr-8855: HERCULES Act](https://policyrisk.com/legislation/116-hr-8855)
- [116-hr-8830: You Must Be Alive To Vote Act of 2020](https://policyrisk.com/legislation/116-hr-8830)
- [116-hr-8702: Holding Providers Harmless From Medicare Cuts During COVID–19 Act of 2020](https://policyrisk.com/legislation/116-hr-8702)
- [116-hr-12: CTF Act](https://policyrisk.com/legislation/116-hr-12)
- [116-hr-8621: Child Tax Credit for Pregnant Moms Act of 2020](https://policyrisk.com/legislation/116-hr-8621)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/116-hr-8987 (as of 2025-11-18).